BI’s Article search uses Boolean search capabilities. If you are not familiar with these principles, here are some quick tips.
To search specifically for more than one word, put the search term in quotation marks. For example, “workers compensation”. This will limit your search to that combination of words.
To search for a combination of terms, use quotations and the & symbol. For example, “hurricane” & “loss”.
Reprints
Pharmaceutical benefit managers are often choosing higher-priced options as biosimilar competitors to Humira hit the market, Becker’s Payer Issues reports. Humira, used to treat rheumatoid arthritis and other conditions, can cost upward of $9,000 a month, according to GoodRx. The drug's first biologic competitor, Amjevita, is offered at two different prices: around $85,500 a year, about 5% less than Humira; and around $40,500 a year, about 55% of Humira's cost.
1. UnitedHealthcare faces backlash over prior authorization policy
2. House panel asks Cigna for details on controversial claims denials
3. Coalition opposed to UnitedHealthcare prior authorization grows
4. Million-dollar health care claims are rising for self-insureds
6. Benefytt Technologies files for bankruptcy after paying fraud settlements